In a separate development, Abbott has announced the first global procedures using its new Volt Pulsed Field Ablation (PFA) System for the treatment of patients with atrial fibrillation (AFib). The Proclaim DRG system's compatibility with 50cm SlimTip DRG further enhances its utility. Pedro Malha, vice president of Abbott's neuromodulation business said: “As we continue to work holistically across chronic pain care, we are excited to see this new MRI expanded indication for our proprietary and unique Dorsal Root Ganglion Stimulation therapy become another valuable tool in the hands of treating physicians helping people get back to living a life on their terms.” The system has been shown to significantly alleviate pain and enhance the quality of life for four out of five patients receiving the therapy. The Proclaim DRG system, the only FDA-approved dorsal root ganglion (DRG) stimulation therapy, offers targeted relief for individuals with complex regional pain syndrome (CRPS) types I and II in the lower limbs by DRG stimulation. This development allows patients implanted with the device to undergo full-body MRI scans. The US Food and Drug Administration (FDA) has granted approval of expanded MRI labelling for Abbott's Proclaim DRG neurostimulation system. The Proclaim system offers targeted relief for individuals with complex regional pain syndrome types I and II in the lower limbs. FDA approves expanded MRI labelling for Abbott's neurostimulator
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |